利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.024 秒)

    "> DIAGONSIS AND TREATMENT OF AUTOIMMUNE DISEASES BY TARGETING AUTOIMMUNE-RELATED B CELLS (
    2.
    发明申请
    DIAGONSIS AND TREATMENT OF AUTOIMMUNE DISEASES BY TARGETING AUTOIMMUNE-RELATED B CELLS ("ABCS") 审中-公开
    通过靶向自动免疫相关B细胞（“ABCS”）对自身免疫疾病的诊断和治疗

    公开(公告)号：US20140037645A1

    公开(公告)日：2014-02-06

    申请号：US13876109

    申请日：2009-11-09

    申请人： Anatoly Rubtsov ,  John Kappler ,  Philippa Marrack

    发明人： Anatoly Rubtsov ,  John Kappler ,  Philippa Marrack

    IPC分类号： G01N33/68 ,  C12Q1/68

    CPC分类号： G01N33/6893 ,  C12Q1/6837 ,  G01N33/5091 ,  G01N33/5094 ,  G01N33/564 ,  G01N2333/70553

    摘要： The present invention is directed to methods of diagnosis and treatment of autoimmune diseases based on the identification of a novel population of B cells known as Autoimmune- or Age-related B cells (“ABCs”). These cells express the CDI Ic cell surface protein and exhibit a unique gene expression profile. The ABCs increase in numbers in subjects that are prone to developing autoimmune diseases or in healthy individuals, particularly females, as they age. Accordingly, the present invention includes methods and kits for diagnosis of autoimmune diseases based on the detection of the ABCs before overt symptoms of the disease become detectable. The present invention also includes methods of treatment of autoimmune diseases by targeting the ABCs, as well as methods for assessing the efficacy of treatments of autoimmune diseases.

    摘要翻译： 本发明涉及基于鉴定称为自身免疫或年龄相关B细胞（“ABCs”）的新型B细胞群体来诊断和治疗自身免疫性疾病的方法。 这些细胞表达CDI 1c细胞表面蛋白并显示独特的基因表达谱。 随着年龄的增长，ABC容易发生自身免疫性疾病的受试者或健康个体尤其是女性的个体数量增加。 因此，本发明包括用于诊断自身免疫性疾病的方法和试剂盒，其基于在疾病的明显症状变得可检测之前检测到ABC。 本发明还包括通过靶向ABCs来治疗自身免疫性疾病的方法，以及评估自身免疫疾病治疗功效的方法。

    Product and process for T cell regulation
    9.
    发明授权
    Product and process for T cell regulation 失效
    T细胞调节的产物和方法

    公开(公告)号：US5820866A

    公开(公告)日：1998-10-13

    申请号：US207481

    申请日：1994-03-04

    申请人： John W. Kappler ,  Philippa Marrack

    发明人： John W. Kappler ,  Philippa Marrack

    IPC分类号： C12N15/09 ,  A61K35/12 ,  A61K35/18 ,  A61K39/00 ,  A61K48/00 ,  A61P37/00 ,  C07K14/47 ,  C07K14/74 ,  C07K14/77 ,  C07K14/80 ,  C07K19/00 ,  C12N5/10 ,  C12N15/85 ,  A61K39/385

    CPC分类号： C07K14/80 ,  C07K14/70539 ,  C07K14/77 ,  C12N15/8509 ,  A01K2217/05 ,  A01K2217/30 ,  A01K2267/0325 ,  A61K48/00 ,  C07K2319/00 ,  C12N2799/026

    摘要： The present invention relates to a product and process for regulating the activity of T cells using major histocompatibility complexes (MHC) stably linked to antigenic peptides. Disclosed is an antigenic peptide covalently linked to a major histocompatibility complex (MHC) protein by a novel linker, thereby enabling the formation of a stable peptide-MHC complex, alone or in combination with additional MHC protein chains, capable of being recognized by a T cell receptor (TCR). Also disclosed is a nucleic molecule having a sequence encoding a Peptide-L-MHC molecule comprising an antigenic peptide joined by a linker to an MHC segment. The invention is additionally directed to formulations comprising an antigenic peptide joined by a linker to an MHC segment anchored in a lipid-containing substrate. Pharmaceutical reagents are also disclosed which contain an antigenic peptide joined by a linker to an MHC segment combined with a suitable carrier that is capable of presenting the Peptide-L-MHC molecule so that it is capable of being recognized by a T cell receptor.

    摘要翻译： 本发明涉及使用与抗原肽稳定连接的主要组织相容性复合物（MHC）来调节T细胞的活性的产物和方法。 公开了通过新的接头共价连接到主要组织相容性复合物（MHC）蛋白的抗原肽，从而能够单独或与额外的MHC蛋白链组合形成稳定的肽-MHC复合物，其能够被T 细胞受体（TCR） 还公开了具有编码肽-L-MHC分子的序列的核酸分子，其包含通过接头连接到MHC片段的抗原肽。 本发明另外涉及包含通过接头连接到锚定在含脂质底物中的MHC区段的抗原肽的制剂。 还公开了药物试剂，其含有通过接头连接到与能够呈递肽-L-MHC分子的合适载体的MHC区段的抗原肽，使得其能够被T细胞受体识别。